[{"id":"5ab5758f-ded0-479b-83dd-b16b495d0f1a","acronym":"FASCINATE-N","url":"https://clinicaltrials.gov/study/NCT05582499","created_at":"2022-10-17T13:56:00.115Z","updated_at":"2025-02-25T12:29:07.250Z","phase":"Phase 2","brief_title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","source_id_and_acronym":"NCT05582499 - FASCINATE-N","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • CD8 • FOXC1","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD8 • FOXC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 716","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-27"},{"id":"1eeb0f08-7927-4438-a063-9e9859dc3e24","acronym":"","url":"https://clinicaltrials.gov/study/NCT06516289","created_at":"2025-02-26T10:01:45.127Z","updated_at":"2025-02-26T10:01:45.127Z","phase":"Phase 2","brief_title":"Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab","source_id_and_acronym":"NCT06516289","lead_sponsor":"Fudan University","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020) • M9466"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-12-12"},{"id":"fc19fd8b-e7bb-42ac-a2ee-1c0a25c66b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05999149","created_at":"2023-08-21T16:09:23.150Z","updated_at":"2024-07-02T16:35:18.282Z","phase":"Phase 3","brief_title":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)","source_id_and_acronym":"NCT05999149","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 424","initiation":"Initiation: 08/20/2023","start_date":" 08/20/2023","primary_txt":" Primary completion: 08/30/2025","primary_completion_date":" 08/30/2025","study_txt":" Completion: 08/30/2027","study_completion_date":" 08/30/2027","last_update_posted":"2024-02-21"},{"id":"47481f7c-4d73-4ee0-9312-6b63c4d1442d","acronym":"BCTOP-L-M05","url":"https://clinicaltrials.gov/study/NCT05594095","created_at":"2022-10-26T13:56:12.698Z","updated_at":"2024-07-02T16:35:20.799Z","phase":"Phase 2","brief_title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","source_id_and_acronym":"NCT05594095 - BCTOP-L-M05","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-02-06"},{"id":"99d83691-ba98-4e13-a850-14591cdf2f94","acronym":"BCTOP-T-M02","url":"https://clinicaltrials.gov/study/NCT05760378","created_at":"2023-03-08T17:01:48.152Z","updated_at":"2024-07-02T16:35:20.795Z","phase":"Phase 3","brief_title":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.","source_id_and_acronym":"NCT05760378 - BCTOP-T-M02","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • AiRuiKa (camrelizumab) • capecitabine • Halaven (eribulin mesylate) • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 223","initiation":"Initiation: 03/17/2023","start_date":" 03/17/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-06"},{"id":"f56b977b-9d2c-4be8-bb3f-191550b47d48","acronym":"FUTURE-SUPER","url":"https://clinicaltrials.gov/study/NCT04395989","created_at":"2021-01-18T21:12:49.296Z","updated_at":"2024-07-02T16:35:25.372Z","phase":"Phase 2","brief_title":"An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.","source_id_and_acronym":"NCT04395989 - FUTURE-SUPER","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • famitinib (SHR 1020) • Airuituo (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 139","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-22"},{"id":"08ed8e59-4911-4f16-8adf-b0e33efcb65d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04346381","created_at":"2021-01-18T21:01:49.590Z","updated_at":"2024-07-02T16:35:36.686Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT04346381","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020)"],"overall_status":"Completed","enrollment":" Enrollment 233","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 06/22/2022","primary_completion_date":" 06/22/2022","study_txt":" Completion: 06/22/2022","study_completion_date":" 06/22/2022","last_update_posted":"2023-09-18"},{"id":"c8c01e6c-2733-4dd5-8269-1c7a962b4b4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05176080","created_at":"2022-01-04T14:54:23.045Z","updated_at":"2024-07-02T16:35:49.000Z","phase":"Phase 1/2","brief_title":"Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer","source_id_and_acronym":"NCT05176080","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • AiRuiKang (dalpiciclib) • famitinib (SHR 1020)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2023-05-04"},{"id":"9d718a4a-a280-403f-8c25-776772ff621b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04733417","created_at":"2021-02-02T15:52:07.038Z","updated_at":"2024-07-02T16:35:50.733Z","phase":"Phase 2","brief_title":"A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.","source_id_and_acronym":"NCT04733417","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKang (dalpiciclib) • famitinib (SHR 1020)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/26/2021","start_date":" 05/26/2021","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2023-04-12"},{"id":"3c3ffb94-cb73-489b-990b-47cb750aeae7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05670925","created_at":"2023-01-04T14:58:46.378Z","updated_at":"2024-07-02T16:35:54.620Z","phase":"Phase 2","brief_title":"A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.","source_id_and_acronym":"NCT05670925","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • albumin-bound paclitaxel • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2023-02-28"},{"id":"8896a2c7-81ae-49a0-b570-13d2f77ace9c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04680988","created_at":"2021-01-19T20:46:38.959Z","updated_at":"2024-07-02T16:36:00.449Z","phase":"Phase 2","brief_title":"A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer","source_id_and_acronym":"NCT04680988","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • pemetrexed • famitinib (SHR 1020)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 194","initiation":"Initiation: 04/05/2021","start_date":" 04/05/2021","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2022-11-15"},{"id":"6fe8f0e9-8178-43af-8474-eda668b88de5","acronym":"MULAN","url":"https://clinicaltrials.gov/study/NCT04355858","created_at":"2021-01-18T21:03:24.371Z","updated_at":"2024-07-02T16:36:06.637Z","phase":"Phase 2","brief_title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","source_id_and_acronym":"NCT04355858 - MULAN","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020) • SHR7390 • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 319","initiation":"Initiation: 05/01/2020","start_date":" 05/01/2020","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-07-26"},{"id":"e4e5efab-6ae9-41b4-895d-bcdc74c749c5","acronym":"SHR-1210-II-213","url":"https://clinicaltrials.gov/study/NCT03827837","created_at":"2021-01-18T18:54:16.293Z","updated_at":"2024-07-02T16:36:07.859Z","phase":"Phase 2","brief_title":"Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors","source_id_and_acronym":"NCT03827837 - SHR-1210-II-213","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 01/23/2019","start_date":" 01/23/2019","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-07-01"},{"id":"421a32ec-a9a1-4a0f-bc1f-808eb56ef6d8","acronym":"CSSG-02","url":"https://clinicaltrials.gov/study/NCT03997747","created_at":"2021-01-18T19:39:08.962Z","updated_at":"2024-07-02T16:36:09.415Z","phase":"","brief_title":"Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS","source_id_and_acronym":"NCT03997747 - CSSG-02","lead_sponsor":"Peking University People's Hospital","biomarkers":" TMB • IFNG","pipe":"","alterations":" ","tags":["TMB • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2022-06-03"},{"id":"538c5636-3e4e-4807-a35a-7c344d858490","acronym":"","url":"https://clinicaltrials.gov/study/NCT05208177","created_at":"2022-01-26T13:54:00.695Z","updated_at":"2024-07-02T16:36:09.697Z","phase":"Phase 2","brief_title":"A Study of SHR-1802 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT05208177","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020) • SHR-1802"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 04/22/2022","start_date":" 04/22/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-05-27"},{"id":"e3edb4a1-753a-425e-8447-f64bfa45e83e","acronym":"FUTURE-C-PLUS","url":"https://clinicaltrials.gov/study/NCT04129996","created_at":"2021-01-18T20:10:31.991Z","updated_at":"2024-07-02T16:36:18.672Z","phase":"Phase 2","brief_title":"A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)","source_id_and_acronym":"NCT04129996 - FUTURE-C-PLUS","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • albumin-bound paclitaxel • famitinib (SHR 1020)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 09/01/2022","study_completion_date":" 09/01/2022","last_update_posted":"2022-01-11"},{"id":"f031d490-f72f-4ccf-936b-47d3a82dc201","acronym":"CAMFA-L","url":"https://clinicaltrials.gov/study/NCT05005468","created_at":"2021-08-13T12:53:39.930Z","updated_at":"2024-07-02T16:36:26.350Z","phase":"Phase 2","brief_title":"A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.","source_id_and_acronym":"NCT05005468 - CAMFA-L","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" EGFR • ALK","pipe":"","alterations":" ","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2021-08-13"},{"id":"1b53023c-c1c2-44d8-8060-9a7cedca3e1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04479904","created_at":"2021-01-19T20:05:45.741Z","updated_at":"2024-07-02T16:36:28.774Z","phase":"Phase 2","brief_title":"A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT04479904","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e famitinib (SHR 1020)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/10/2020","start_date":" 08/10/2020","primary_txt":" Primary completion: 12/10/2021","primary_completion_date":" 12/10/2021","study_txt":" Completion: 02/10/2022","study_completion_date":" 02/10/2022","last_update_posted":"2021-06-22"},{"id":"9590d6e3-ce36-476e-ae80-02d2bc5d0231","acronym":"","url":"https://clinicaltrials.gov/study/NCT04619433","created_at":"2021-01-19T20:34:11.180Z","updated_at":"2024-07-02T16:36:33.252Z","phase":"Phase 3","brief_title":"A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.","source_id_and_acronym":"NCT04619433","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • AiRuiKa (camrelizumab) • pemetrexed • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 560","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 10/15/2023","study_completion_date":" 10/15/2023","last_update_posted":"2021-03-16"},{"id":"0908c331-4cb7-45af-982e-ed855c525341","acronym":"EBAOFC","url":"https://clinicaltrials.gov/study/NCT03919539","created_at":"2021-01-18T19:17:15.593Z","updated_at":"2024-07-02T16:36:50.416Z","phase":"","brief_title":"Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab","source_id_and_acronym":"NCT03919539 - EBAOFC","lead_sponsor":"Peking University People's Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2020-02-06"},{"id":"b7d68cd2-4b13-49f4-9f9a-c6f2f9eb34b0","acronym":"FMTN-I-LNPC","url":"https://clinicaltrials.gov/study/NCT01462474","created_at":"2021-01-18T06:05:00.050Z","updated_at":"2024-07-02T16:37:11.408Z","phase":"Phase 1","brief_title":"Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT01462474 - FMTN-I-LNPC","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" KIT • KDR","pipe":"","alterations":" ","tags":["KIT • KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • famitinib (SHR 1020)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2018-04-18"}]